Effect of neoadjuvant chemotherapy on ERCC1 gene expression in breast cancer.
- Author:
Jian-Min FU
1
;
Jie ZHOU
;
Jian-Sheng XIE
;
Hui LI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Breast Neoplasms; drug therapy; genetics; Carcinoma, Ductal, Breast; drug therapy; genetics; metabolism; DNA-Binding Proteins; genetics; Endonucleases; genetics; Etoposide; administration & dosage; Female; Gene Expression Regulation, Neoplastic; drug effects; Humans; Middle Aged; Neoadjuvant Therapy; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; administration & dosage
- From: Journal of Southern Medical University 2008;28(4):603-605
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression of ERCC1 gene in breast cancer before and after neo-adjuvant chemotherapy.
METHODSThe expression of ERCC1 gene was detected by RT-PCR in 40 breast cancer patients and in 14 patients treated with neoadjuvant chemotherapy.
RESULTSPositive expression of ERCC1 gene was detected by RT-PCR in 35.0% of the breast cancer specimens, and ERCC1 expression was not correlated to the patients' age, tumor size, axillary lymph node metastasis, pathological type, histological grade, ER, PR or HER-2 (P>0.05). ERCC1 gene expression was significantly higher in neo-adjuvant chemotherapy group than in non-chemotherapy group (P<0.05).
CONCLUSIONThe expression of ERCC1 gene does not affect the clinical and pathological features of breast cancer. Neo-adjuvant chemotherapy can increase the expression of ERCC1 gene, due attention should be given to with in subsequent chemotherapy.
